2Seventy Bio saw the highest growth of 1.66% in patent filings in April and 1.49% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.66% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of 2Seventy Bio’s patent filings and grants. Buy the databook here.
2Seventy Bio has been focused on protecting inventions in European Patent Office(EPO) with eight publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings with nearly 50% of filings. The European Patent Office(EPO), Denmark(DK), United States(US), and Israel(IL) patent Office are among the top ten patent offices where 2Seventy Bio is filings its patents. Among the top granted patent authorities, 2Seventy Bio has 43% of its grants in United States(US), 29% in Israel(IL) and 14% in Australia(AU).
Immatics and University of Pennsylvania could be the strongest competitors for 2Seventy Bio
Patents related to genomics and nanomedicine lead 2Seventy Bio's portfolio
2Seventy Bio has the highest number of patents in genomics followed by, nanomedicine and cell & gene therapy. For genomics, nearly 50% of patents were filed and 33% of patents were granted in Q2 2024.
Cell therapy related patents lead 2Seventy Bio portfolio followed by leukemia, and sarcomas
2Seventy Bio has highest number of patents in cell therapy followed by leukemia, sarcomas, advanced malignancy, and lymphoma. For cell therapy, nearly 67% of patents were filed and 2% of patents were granted in Q2 2024.
For comprehensive analysis of 2Seventy Bio's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.